Abraham, G., Friedman, R. H., Verghese, C., et al (1995) Osteoporosis and schizophrenia: can we limit known risk factors?
Biological Psychiatry, 38, 131–132.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Andreason, N. (1983) Scale for Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
Bilici, M., Cakirbay, H., Guler, M., et al (2002) Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. International Journal of Neuroscience, 112, 817–828.
Davies, M. C., Gulekli, B. & Jacobs, H. S. (1995) Osteoporosis in Turners syndrome and other forms of primary amenorrhoea. Clinical Endocrinology (Oxford), 43, 741–745.
Delva, N., Crammer, J. L., Jarzylo, S. V., et al (1989) Osteopenia, pathological fractures, and increased calcium excretion in schizophrenic patients with polydipsia. Biological Psychiatry, 26, 781–793.
Dickson, R., Seeman, M. & Corenblum, B. (2000) Hormonal side effects in women: typical versus atypical antipsychotic treatment. Journal of Clinical Psychiatry, 61 (suppl. 3), 10–15.
Halbreich, U., Rojansky, N., Palter, S., et al (1995) Decreased bone mineral density in medicated psychiatric patients. Psychosomatic Medicine, 57, 485–491.
Hobson, E. E. & Ealston, S. H. (2001) Role of genetic factors in the pathophysiology and management of osteoporosis. Clinical Endocrinology (Oxford), 54, 1–9.
Kapur, S., Zipursky, R., Jones, C., et al (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514–520.
Kinon, B. J., Gilmore, J. A., Liu, H., et al (2003) Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medication or risperidone. Psychoneuroendocrinology, 28, 55–68.
Naidoo, U., Goff, D. C. & Klibanski, A. (2003) Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology, 28 (suppl. 2), 97–108.
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.
Schlecter, J. A., Sherman, B. & Martin, R. (1983) Bone density in amenorrheic women with and without hyperprolactinaemia. Journal of Clinical Endocrinology and Metabolism, 56, 1120–1123.
Seeman, P. (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261–284.
Smith, S., Wheeler, M., Murray, R., et al (2002) The effects of anti-psychotic induced hyperprolactinaemia on the hypothalamic–pituitary–gonadal axis. Journal of Clinical Psychopharmacology, 22, 109–114.
Taylor, D., McConnell, H., McConnell, D., et al (2001) The Maudsley 2001 Prescribing Guidelines (6th edn). London: Martin Dunitz.
Veldman, R. G., Frolich, M., Pincus, S. M., et al (2001) Basal, pulsatile, entropic and 24-hour features of secondary hyperprolactinaemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinaemia. Journal of Clinical Endocrinology and Metabolism, 86, 1562–1567.
Wieck, A. & Haddad, P. M. (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. British Journal of Psychiatry, 182, 199–204.
World Health Organization Study Group (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Report of a WHO Study Group. WHO Technical Report Series no. 843, pp. 1–12. Geneva: WHO.